ArticleWiener klinische Wochenschrift2011
Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.
Article in Wiener klinische Wochenschrift, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- An updated meta-analysis of transforming growth factor-β1 gene: three polymorphisms with gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- TGF-β2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer: A STROBE-compliant article.Medicine · 2020Observational
- TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer.Journal of cellular and molecular medicine · 2020Article
- Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers.American journal of cancer research · 2017Article
- Influence of TGFB1 C-509T polymorphism on gastric cancer risk associated with TGF-β1 expression in the gastric mucosa.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2015Article
- Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).Biomedical reports · 2013Article
- Article
- Immunohistochemical biomarkers in gastric cancer research and management.International journal of surgical oncology · 2012Article
- Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas.Gastroenterology research and practice · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is still the most prevalent neoplasia in many countries. Therefore, besides the clinicopathological factors known to be prognostic markers, new independent parameters are being investigated. This study was to investigate the expression of transforming growth factor - β1 (TGF-β1) and transforming growth factor - β1 receptor II (TGF-β1RII) in HER2/neu negative gastric carcinomas and to explore the correlations, the clinicopathological characteristics and prognosis of gastric carcinoma. PATIENTS AND
methodsSurgical specimens from 42 patients with gastric cancer were examined for the presence of HER2/neu, TGF-β1 and TGF-β1RII by immunohistochemistry. The correlation between expression of the proteins and patient clinicopathological parameters was evaluated and the prognostic significance of TGF-β1 and of receptor expression was assessed.
resultsAll specimens demonstrated HER2/neu-negative status. TGF-β1 analyses exhibited predominantly cytoplasmic and membranous immunostaining. We found that 80% of intestinal gastric cancer specimens have TGF-β1 expression, while in the diffuse type they are 43%. Also the tumors with low and moderate differentiation were positive for TGF-βRII (p = 0.041). Finally we found that median survival period of the patients was 37.03 months and the patients with TGF-β1 expression had worse prognosis after surgical therapy compared to those without expression of TGF-β1 (p = 0.034).
conclusionsWe have shown that TGF-β1 expression in gastric tumor tissue with HER2/neu-negative status is of prognostic relevance in gastric cancer. The data for TGF-β1 and TGF-βRII expression showed association with clinicopathological parameters, and more precisely with the differentiation and histology type and TGF-β1-positive patient had a shorter overall survival compared with TGF-β1-negative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.